 | • レポートコード：QFJ1-4576 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥546,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥819,000 (USD5,850) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査レポートでは、好中球減少症生物学的製剤治療の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（フィルグラスチム、ペグフィルグラスチム、レノグラスチム、リペグフィルグラスチム、サルグラモスチム）、用途別市場規模（小売薬局、病院薬局、オンライン薬局）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・好中球減少症生物学的製剤治療の市場動向 ・企業の競争状況、市場シェア ・好中球減少症生物学的製剤治療の種類別市場規模と予測2016-2027（フィルグラスチム、ペグフィルグラスチム、レノグラスチム、リペグフィルグラスチム、サルグラモスチム） ・好中球減少症生物学的製剤治療の用途別市場規模と予測2016-2027（小売薬局、病院薬局、オンライン薬局） ・好中球減少症生物学的製剤治療の北米市場規模2016-2027（アメリカ、カナダ） ・好中球減少症生物学的製剤治療の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・好中球減少症生物学的製剤治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・好中球減少症生物学的製剤治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・好中球減少症生物学的製剤治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Teva Pharmaceutical、Amgen、Sanofi、Mylan(Fulphila)、Kyowa Kirin、Novartis、Spectrum Pharmaceuticals、Pfizer、Baxter International、Partner Therapeutics(Leukine)、BeyondSpring Pharmaceuticals、Cellerant Therapeutics、Enzychem Lifesciences Corporation、Myelo Therapeutics、Generon） ・結論 |
Neutropenia is a clinical condition characterized by a decrease in neutrophil count in the blood, resulting in a higher risk of developing serious infections. A neutrophil is a type of white blood cell, which helps in fighting infections. The major causes of neutropenia include cancer chemotherapy, infections, bone marrow disorders, autoimmune disorders, and the use of specific drugs.
Market Analysis and Insights: Global Neutropenia Biologic Drug Treatment Market
The global Neutropenia Biologic Drug Treatment market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Neutropenia Biologic Drug Treatment market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Neutropenia Biologic Drug Treatment market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Neutropenia Biologic Drug Treatment market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Neutropenia Biologic Drug Treatment market.
Global Neutropenia Biologic Drug Treatment Scope and Market Size
Neutropenia Biologic Drug Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Neutropenia Biologic Drug Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
By Drug Type
Filgrastim
Pegfilgrastim
Lenograstim
Lipegfilgrastim
Sargramostim
By Treatment Type
Antibiotic Drugs
Granulocyte-Colony-Stimulating Factor (G-CSF)
Antifungal Drugs
Others
Segment by Application
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Teva Pharmaceutical
Amgen
Sanofi
Mylan(Fulphila)
Kyowa Kirin
Novartis
Spectrum Pharmaceuticals
Pfizer
Baxter International
Partner Therapeutics(Leukine)
BeyondSpring Pharmaceuticals
Cellerant Therapeutics
Enzychem Lifesciences Corporation
Myelo Therapeutics
Generon
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Filgrastim
1.2.3 Pegfilgrastim
1.2.4 Lenograstim
1.2.5 Lipegfilgrastim
1.2.6 Sargramostim
1.3 Market by Application
1.3.1 Global Neutropenia Biologic Drug Treatment Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Neutropenia Biologic Drug Treatment Market Perspective (2016-2027)
2.2 Neutropenia Biologic Drug Treatment Growth Trends by Regions
2.2.1 Neutropenia Biologic Drug Treatment Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neutropenia Biologic Drug Treatment Historic Market Share by Regions (2016-2021)
2.2.3 Neutropenia Biologic Drug Treatment Forecasted Market Size by Regions (2022-2027)
2.3 Neutropenia Biologic Drug Treatment Industry Dynamic
2.3.1 Neutropenia Biologic Drug Treatment Market Trends
2.3.2 Neutropenia Biologic Drug Treatment Market Drivers
2.3.3 Neutropenia Biologic Drug Treatment Market Challenges
2.3.4 Neutropenia Biologic Drug Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue
3.1.1 Global Top Neutropenia Biologic Drug Treatment Players by Revenue (2016-2021)
3.1.2 Global Neutropenia Biologic Drug Treatment Revenue Market Share by Players (2016-2021)
3.2 Global Neutropenia Biologic Drug Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neutropenia Biologic Drug Treatment Revenue
3.4 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio
3.4.1 Global Neutropenia Biologic Drug Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neutropenia Biologic Drug Treatment Revenue in 2020
3.5 Neutropenia Biologic Drug Treatment Key Players Head office and Area Served
3.6 Key Players Neutropenia Biologic Drug Treatment Product Solution and Service
3.7 Date of Enter into Neutropenia Biologic Drug Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Neutropenia Biologic Drug Treatment Breakdown Data by Type
4.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Type (2016-2021)
4.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2022-2027)
5 Neutropenia Biologic Drug Treatment Breakdown Data by Application
5.1 Global Neutropenia Biologic Drug Treatment Historic Market Size by Application (2016-2021)
5.2 Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Neutropenia Biologic Drug Treatment Market Size (2016-2027)
6.2 North America Neutropenia Biologic Drug Treatment Market Size by Type
6.2.1 North America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021)
6.2.2 North America Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027)
6.2.3 North America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2027)
6.3 North America Neutropenia Biologic Drug Treatment Market Size by Application
6.3.1 North America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021)
6.3.2 North America Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027)
6.3.3 North America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2027)
6.4 North America Neutropenia Biologic Drug Treatment Market Size by Country
6.4.1 North America Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021)
6.4.2 North America Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Neutropenia Biologic Drug Treatment Market Size (2016-2027)
7.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type
7.2.1 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021)
7.2.2 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027)
7.2.3 Europe Neutropenia Biologic Drug Treatment Market Size by Type (2016-2027)
7.3 Europe Neutropenia Biologic Drug Treatment Market Size by Application
7.3.1 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021)
7.3.2 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027)
7.3.3 Europe Neutropenia Biologic Drug Treatment Market Size by Application (2016-2027)
7.4 Europe Neutropenia Biologic Drug Treatment Market Size by Country
7.4.1 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021)
7.4.2 Europe Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size (2016-2027)
8.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type
8.2.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2016-2027)
8.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application
8.3.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2016-2027)
8.4 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region
8.4.1 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Neutropenia Biologic Drug Treatment Market Size (2016-2027)
9.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Type
9.2.1 Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021)
9.2.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027)
9.2.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2027)
9.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Application
9.3.1 Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021)
9.3.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027)
9.3.3 Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2027)
9.4 Latin America Neutropenia Biologic Drug Treatment Market Size by Country
9.4.1 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021)
9.4.2 Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size (2016-2027)
10.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type
10.2.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2016-2027)
10.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application
10.3.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2016-2027)
10.4 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country
10.4.1 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Teva Pharmaceutical
11.1.1 Teva Pharmaceutical Company Details
11.1.2 Teva Pharmaceutical Business Overview
11.1.3 Teva Pharmaceutical Neutropenia Biologic Drug Treatment Introduction
11.1.4 Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.1.5 Teva Pharmaceutical Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Neutropenia Biologic Drug Treatment Introduction
11.2.4 Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Details
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Neutropenia Biologic Drug Treatment Introduction
11.3.4 Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.3.5 Sanofi Recent Development
11.4 Mylan(Fulphila)
11.4.1 Mylan(Fulphila) Company Details
11.4.2 Mylan(Fulphila) Business Overview
11.4.3 Mylan(Fulphila) Neutropenia Biologic Drug Treatment Introduction
11.4.4 Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.4.5 Mylan(Fulphila) Recent Development
11.5 Kyowa Kirin
11.5.1 Kyowa Kirin Company Details
11.5.2 Kyowa Kirin Business Overview
11.5.3 Kyowa Kirin Neutropenia Biologic Drug Treatment Introduction
11.5.4 Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.5.5 Kyowa Kirin Recent Development
11.6 Novartis
11.6.1 Novartis Company Details
11.6.2 Novartis Business Overview
11.6.3 Novartis Neutropenia Biologic Drug Treatment Introduction
11.6.4 Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.6.5 Novartis Recent Development
11.7 Spectrum Pharmaceuticals
11.7.1 Spectrum Pharmaceuticals Company Details
11.7.2 Spectrum Pharmaceuticals Business Overview
11.7.3 Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
11.7.4 Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.7.5 Spectrum Pharmaceuticals Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Details
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Neutropenia Biologic Drug Treatment Introduction
11.8.4 Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.8.5 Pfizer Recent Development
11.9 Baxter International
11.9.1 Baxter International Company Details
11.9.2 Baxter International Business Overview
11.9.3 Baxter International Neutropenia Biologic Drug Treatment Introduction
11.9.4 Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.9.5 Baxter International Recent Development
11.10 Partner Therapeutics(Leukine)
11.10.1 Partner Therapeutics(Leukine) Company Details
11.10.2 Partner Therapeutics(Leukine) Business Overview
11.10.3 Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Introduction
11.10.4 Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.10.5 Partner Therapeutics(Leukine) Recent Development
11.11 BeyondSpring Pharmaceuticals
11.11.1 BeyondSpring Pharmaceuticals Company Details
11.11.2 BeyondSpring Pharmaceuticals Business Overview
11.11.3 BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Introduction
11.11.4 BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.11.5 BeyondSpring Pharmaceuticals Recent Development
11.12 Cellerant Therapeutics
11.12.1 Cellerant Therapeutics Company Details
11.12.2 Cellerant Therapeutics Business Overview
11.12.3 Cellerant Therapeutics Neutropenia Biologic Drug Treatment Introduction
11.12.4 Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.12.5 Cellerant Therapeutics Recent Development
11.13 Enzychem Lifesciences Corporation
11.13.1 Enzychem Lifesciences Corporation Company Details
11.13.2 Enzychem Lifesciences Corporation Business Overview
11.13.3 Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Introduction
11.13.4 Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.13.5 Enzychem Lifesciences Corporation Recent Development
11.14 Myelo Therapeutics
11.14.1 Myelo Therapeutics Company Details
11.14.2 Myelo Therapeutics Business Overview
11.14.3 Myelo Therapeutics Neutropenia Biologic Drug Treatment Introduction
11.14.4 Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.14.5 Myelo Therapeutics Recent Development
11.15 Generon
11.15.1 Generon Company Details
11.15.2 Generon Business Overview
11.15.3 Generon Neutropenia Biologic Drug Treatment Introduction
11.15.4 Generon Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021)
11.15.5 Generon Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Neutropenia Biologic Drug Treatment Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Filgrastim
Table 3. Key Players of Pegfilgrastim
Table 4. Key Players of Lenograstim
Table 5. Key Players of Lipegfilgrastim
Table 6. Key Players of Sargramostim
Table 7. Global Neutropenia Biologic Drug Treatment Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Neutropenia Biologic Drug Treatment Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Neutropenia Biologic Drug Treatment Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Neutropenia Biologic Drug Treatment Market Share by Regions (2016-2021)
Table 11. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Neutropenia Biologic Drug Treatment Market Share by Regions (2022-2027)
Table 13. Neutropenia Biologic Drug Treatment Market Trends
Table 14. Neutropenia Biologic Drug Treatment Market Drivers
Table 15. Neutropenia Biologic Drug Treatment Market Challenges
Table 16. Neutropenia Biologic Drug Treatment Market Restraints
Table 17. Global Neutropenia Biologic Drug Treatment Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Neutropenia Biologic Drug Treatment Market Share by Players (2016-2021)
Table 19. Global Top Neutropenia Biologic Drug Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2020)
Table 20. Ranking of Global Top Neutropenia Biologic Drug Treatment Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Neutropenia Biologic Drug Treatment Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Neutropenia Biologic Drug Treatment Product Solution and Service
Table 24. Date of Enter into Neutropenia Biologic Drug Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2016-2021)
Table 28. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Neutropenia Biologic Drug Treatment Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2016-2021)
Table 32. Global Neutropenia Biologic Drug Treatment Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size by Country (2022-2027) & (US$ Million)
Table 64. Teva Pharmaceutical Company Details
Table 65. Teva Pharmaceutical Business Overview
Table 66. Teva Pharmaceutical Neutropenia Biologic Drug Treatment Product
Table 67. Teva Pharmaceutical Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 68. Teva Pharmaceutical Recent Development
Table 69. Amgen Company Details
Table 70. Amgen Business Overview
Table 71. Amgen Neutropenia Biologic Drug Treatment Product
Table 72. Amgen Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 73. Amgen Recent Development
Table 74. Sanofi Company Details
Table 75. Sanofi Business Overview
Table 76. Sanofi Neutropenia Biologic Drug Treatment Product
Table 77. Sanofi Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 78. Sanofi Recent Development
Table 79. Mylan(Fulphila) Company Details
Table 80. Mylan(Fulphila) Business Overview
Table 81. Mylan(Fulphila) Neutropenia Biologic Drug Treatment Product
Table 82. Mylan(Fulphila) Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 83. Mylan(Fulphila) Recent Development
Table 84. Kyowa Kirin Company Details
Table 85. Kyowa Kirin Business Overview
Table 86. Kyowa Kirin Neutropenia Biologic Drug Treatment Product
Table 87. Kyowa Kirin Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 88. Kyowa Kirin Recent Development
Table 89. Novartis Company Details
Table 90. Novartis Business Overview
Table 91. Novartis Neutropenia Biologic Drug Treatment Product
Table 92. Novartis Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 93. Novartis Recent Development
Table 94. Spectrum Pharmaceuticals Company Details
Table 95. Spectrum Pharmaceuticals Business Overview
Table 96. Spectrum Pharmaceuticals Neutropenia Biologic Drug Treatment Product
Table 97. Spectrum Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 98. Spectrum Pharmaceuticals Recent Development
Table 99. Pfizer Company Details
Table 100. Pfizer Business Overview
Table 101. Pfizer Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 102. Pfizer Recent Development
Table 103. Baxter International Company Details
Table 104. Baxter International Business Overview
Table 105. Baxter International Neutropenia Biologic Drug Treatment Product
Table 106. Baxter International Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 107. Baxter International Recent Development
Table 108. Partner Therapeutics(Leukine) Company Details
Table 109. Partner Therapeutics(Leukine) Business Overview
Table 110. Partner Therapeutics(Leukine) Neutropenia Biologic Drug Treatment Product
Table 111. Partner Therapeutics(Leukine) Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 112. Partner Therapeutics(Leukine) Recent Development
Table 113. BeyondSpring Pharmaceuticals Company Details
Table 114. BeyondSpring Pharmaceuticals Business Overview
Table 115. BeyondSpring Pharmaceuticals Neutropenia Biologic Drug Treatment Product
Table 116. BeyondSpring Pharmaceuticals Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 117. BeyondSpring Pharmaceuticals Recent Development
Table 118. Cellerant Therapeutics Company Details
Table 119. Cellerant Therapeutics Business Overview
Table 120. Cellerant Therapeutics Neutropenia Biologic Drug Treatment Product
Table 121. Cellerant Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 122. Cellerant Therapeutics Recent Development
Table 123. Enzychem Lifesciences Corporation Company Details
Table 124. Enzychem Lifesciences Corporation Business Overview
Table 125. Enzychem Lifesciences Corporation Neutropenia Biologic Drug Treatment Product
Table 126. Enzychem Lifesciences Corporation Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 127. Enzychem Lifesciences Corporation Recent Development
Table 128. Myelo Therapeutics Company Details
Table 129. Myelo Therapeutics Business Overview
Table 130. Myelo Therapeutics Neutropenia Biologic Drug Treatment Product
Table 131. Myelo Therapeutics Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 132. Myelo Therapeutics Recent Development
Table 133. Generon Company Details
Table 134. Generon Business Overview
Table 135. Generon Neutropenia Biologic Drug Treatment Product
Table 136. Generon Revenue in Neutropenia Biologic Drug Treatment Business (2016-2021) & (US$ Million)
Table 137. Generon Recent Development
Table 138. Research Programs/Design for This Report
Table 139. Key Data Information from Secondary Sources
Table 140. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Neutropenia Biologic Drug Treatment Market Share by Type: 2020 VS 2027
Figure 2. Filgrastim Features
Figure 3. Pegfilgrastim Features
Figure 4. Lenograstim Features
Figure 5. Lipegfilgrastim Features
Figure 6. Sargramostim Features
Figure 7. Global Neutropenia Biologic Drug Treatment Market Share by Application: 2020 VS 2027
Figure 8. Retail Pharmacies Case Studies
Figure 9. Hospital Pharmacies Case Studies
Figure 10. Online Pharmacies Case Studies
Figure 11. Neutropenia Biologic Drug Treatment Report Years Considered
Figure 12. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Neutropenia Biologic Drug Treatment Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Neutropenia Biologic Drug Treatment Market Share by Regions: 2020 VS 2027
Figure 15. Global Neutropenia Biologic Drug Treatment Market Share by Regions (2022-2027)
Figure 16. Global Neutropenia Biologic Drug Treatment Market Share by Players in 2020
Figure 17. Global Top Neutropenia Biologic Drug Treatment Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neutropenia Biologic Drug Treatment as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Neutropenia Biologic Drug Treatment Revenue in 2020
Figure 19. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2016-2021)
Figure 20. Global Neutropenia Biologic Drug Treatment Revenue Market Share by Type (2022-2027)
Figure 21. North America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Neutropenia Biologic Drug Treatment Market Share by Type (2016-2027)
Figure 23. North America Neutropenia Biologic Drug Treatment Market Share by Application (2016-2027)
Figure 24. North America Neutropenia Biologic Drug Treatment Market Share by Country (2016-2027)
Figure 25. United States Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Neutropenia Biologic Drug Treatment Market Share by Type (2016-2027)
Figure 29. Europe Neutropenia Biologic Drug Treatment Market Share by Application (2016-2027)
Figure 30. Europe Neutropenia Biologic Drug Treatment Market Share by Country (2016-2027)
Figure 31. Germany Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Neutropenia Biologic Drug Treatment Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Neutropenia Biologic Drug Treatment Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Neutropenia Biologic Drug Treatment Market Share by Region (2016-2027)
Figure 41. China Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Neutropenia Biologic Drug Treatment Market Share by Type (2016-2027)
Figure 49. Latin America Neutropenia Biologic Drug Treatment Market Share by Application (2016-2027)
Figure 50. Latin America Neutropenia Biologic Drug Treatment Market Share by Country (2016-2027)
Figure 51. Mexico Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Neutropenia Biologic Drug Treatment Market Share by Country (2016-2027)
Figure 57. Turkey Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Neutropenia Biologic Drug Treatment Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Teva Pharmaceutical Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 61. Amgen Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 62. Sanofi Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 63. Mylan(Fulphila) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 64. Kyowa Kirin Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 65. Novartis Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 66. Spectrum Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 67. Pfizer Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 68. Baxter International Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 69. Partner Therapeutics(Leukine) Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 70. BeyondSpring Pharmaceuticals Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 71. Cellerant Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 72. Enzychem Lifesciences Corporation Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 73. Myelo Therapeutics Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 74. Generon Revenue Growth Rate in Neutropenia Biologic Drug Treatment Business (2016-2021)
Figure 75. Bottom-up and Top-down Approaches for This Report
Figure 76. Data Triangulation
Figure 77. Key Executives Interviewed
世界の先天性好中球減少症治療市場規模・現状・予測（2021年-2027年） Congenital neutropenia occurs when an individual has low levels of neutrophils, a type of white blood cells. Neutrophils are made in the bone marrow, which is the spongy tissue found in larger bones such as the vertebrae, ribs, and pelvis. The congenital neutropenia treatment include antibiotics, an…- 世界の発熱性好中球減少症市場規模・現状・予測（2021年-2027年） Febrile neutropenia, one of the most severe complications during cancer chemotherapy, is the development of fever with infection signals. Market Analysis and Insights: Global Febrile Neutropenia Market The global Febrile Neutropenia market size is projected to reach US$ XX million by 2027, from US$ …
- 世界の調剤薬局市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Compounding Pharmacies Market The global Compounding Pharmacies market size is projected to reach US$ 13500 million by 2027, from US$ 11180 million in 2020, at a CAGR of 2.7% during 2021-2027. With industry-standard accuracy in analysis and high data integrity, t…
- 化学療法による好中球減少薬のグローバル市場調査 2019年 The global Chemotherapy Induced Neutropenia Drug market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. This report focuses on Chemotherapy Induced Neutropenia Drug volume and value at global level, regional level and company le…
- 世界の向精神薬市場規模・現状・予測（2021年-2027年） The majority of essential psychotropic drugs are indicated to treat symptoms of mental disorders, slow down course of mental disorders, diminish disability and avoid relapse in a patient. Market Analysis and Insights: Global Psychotropic Drug Market The global Psychotropic Drug market size is projec…